Cargando…

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies

Neuropathological investigations report that in synucleinopathies with dementia, namely Parkinson’s disease (PD) with dementia (PDD) and dementia with Lewy bodies (DLB), the histopathological hallmarks of Alzheimer’s Disease (AD), in particular amyloid plaques, are frequently observed. In this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellomo, Giovanni, Paolini Paoletti, Federico, Chipi, Elena, Petricciuolo, Maya, Simoni, Simone, Tambasco, Nicola, Parnetti, Lucilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760640/ https://www.ncbi.nlm.nih.gov/pubmed/33256252 http://dx.doi.org/10.3390/diagnostics10121015

Ejemplares similares

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer’s Disease and Other Neurological Disorders
por: Bellomo, Giovanni, et al.
Publicado: (2021)

Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers
por: Farotti, Lucia, et al.
Publicado: (2020)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

PEG-J replacement for duodenal levodopa infusion in Parkinson’s disease patients: a retrospective study
por: Simoni, Simone, et al.
Publicado: (2022)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer’s Disease
por: Barba, Lorenzo, et al.
Publicado: (2022)

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders
por: Tambasco, Nicola, et al.
Publicado: (2022)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
por: Paolini Paoletti, Federico, et al.
Publicado: (2020)

Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington’s and Parkinson’s disease
por: Barschke, Peggy, et al.
Publicado: (2022)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
por: Tambasco, Nicola, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
por: Mukaetova-Ladinska, Elizabeta B., et al.
Publicado: (2010)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia
por: Maetzler, Walter, et al.
Publicado: (2012)

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies
por: Foska, Aikaterini, et al.
Publicado: (2022)

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies
por: Chiasserini, Davide, et al.
Publicado: (2015)

Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
por: Persichetti, Emanuele, et al.
Publicado: (2014)

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
por: Chipi, Elena, et al.
Publicado: (2019)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia
por: Spitzer, Philipp, et al.
Publicado: (2011)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
por: van de Beek, M., et al.
Publicado: (2020)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson’s Disease and Lewy Body Dementia
por: Maetzler, Walter, et al.
Publicado: (2016)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis
por: Parnetti, Lucilla, et al.
Publicado: (2019)

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias
por: Bolsewig, Katharina, et al.
Publicado: (2022)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

α‐Synuclein RT‐QuIC assay in cerebrospinal fluid of patients with dementia with Lewy bodies
por: Bongianni, Matilde, et al.
Publicado: (2019)

Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies
por: Moors, Tim E., et al.
Publicado: (2018)

Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies
por: Perra, Daniela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aelsdvf4t94vcq8cielp45va7o